Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098588789> ?p ?o ?g. }
- W2098588789 endingPage "1824" @default.
- W2098588789 startingPage "1819" @default.
- W2098588789 abstract "No AccessJournal of UrologyINVESTIGATIVE UROLOGY1 Nov 2000PSP94 EXPRESSION AFTER ANDROGEN DEPRIVATION THERAPY: A COMPARATIVE STUDY WITH PROSTATE SPECIFIC ANTIGEN IN BENIGN PROSTATE AND PROSTATE CANCER YUSHI IMASATO, JIM W. XUAN, HIDEKI SAKAI, JONATHAN I. IZAWA, YUTAKA SAITO, JOSEPH L. CHIN, and MADELEINE MOUSSA YUSHI IMASATOYUSHI IMASATO More articles by this author , JIM W. XUANJIM W. XUAN More articles by this author , HIDEKI SAKAIHIDEKI SAKAI More articles by this author , JONATHAN I. IZAWAJONATHAN I. IZAWA Financial interest and/or other relationship with M.D. Anderson Cancer Center. More articles by this author , YUTAKA SAITOYUTAKA SAITO More articles by this author , JOSEPH L. CHINJOSEPH L. CHIN More articles by this author , and MADELEINE MOUSSAMADELEINE MOUSSA More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67113-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: To examine the clinical use of PSP94 (prostate secretory protein of 94 amino acids) as an androgen independent marker, we conducted a comparative study of prostate samples including benign tissue and cancers which did and did not have androgen deprivation. Materials and Methods: Among 163 radical prostatectomy cases 75 had androgen deprivation before operation, while surgery was performed in the remainder without prior hormone treatment. Considering the pathological up grading following hormone therapy, contiguous sections from radical prostatectomy samples were stained for PSP94 and prostate specific antigen (PSA) by immunohistochemistry, and equivalent tumor foci were evaluated by assessing the intensity and extent of the staining. Results: In untreated benign prostate tissue PSP94 and PSA staining was positive and identical in all sections in the no pretreatment group. However, PSP94 expression in the androgen deprivation group was significantly higher than PSA in intensity (p = 0.0005) and extent (p = 0.034). In untreated cancer cases PSP94 intensity and extent demonstrated strong inverse association with Gleason grade (p <0.0001). In contrast, PSA expression was high in every grade, resulting in no statistical association with tumor grade. In the androgen deprivation group PSA staining was decreased in every grade compared to the no pretreatment group. On the other hand, PSP94 expression was decreased in grade 3 tumor foci but increased in grades 4 and 5 tumor foci compared with samples of the corresponding grade in the no pretreatment group (p = 0.0034). Conclusions: PSP94 expression in benign prostate persists under androgen deprivation compared to PSA. PSP94 synthesis in high grade tumor appears to be activated in the absence of androgen stimulation, indicating the possible alternative pathways in the regulation of PSP94. References 1 : Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer1991; 68: 821. Google Scholar 2 : Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy. Prostate1985; 7: 195. Google Scholar 3 : Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology1996; 48: 326. Google Scholar 4 : Serum bound forms of PSP94 (prostate secretory protein of 94 amino acids) in prostate cancer patients. J Cell Biochem1999; 76: 71. Google Scholar 5 : A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. Cancer Lett1993; 70: 159. Google Scholar 6 : Prostatic inhibin-like peptide quantified in urine of prostatic cancer patients by enzyme-linked immunosorbent assay. Clin Chem1989; 35: 1376. Google Scholar 7 : Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma. Prostate1993; 23: 201. Google Scholar 8 : Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate1988; 12: 39. Google Scholar 9 : The potential use of prostatic secretory protein of 94 amino acid residues (PSP94) as a serum marker for prostatic tumor. Urol Res1993; 21: 227. Google Scholar 10 : β-microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinoma. Prostate1993; 22: 347. Google Scholar 11 : Cellular expression of β-microseminoprotein (β-MSP) mRNA and its protein in untreated prostate cancer. Prostate1998; 35: 109. Google Scholar 12 : Prognostic significance of β-microseminoprotein mRNA expression in prostate cancer. Prostate1999; 38: 278. Google Scholar 13 : Expression of Zn-alpha2-glycoprotein and PSP-94 in prostatic adenocarcinoma: an immunohistochemical study of 88 cases. Am J Pathol1990; 136: 1147. Google Scholar 14 : Prognostic significance of antigenic heterogeneity, Gleason grade, and ploidy of lymph node metastases in patients with prostate cancer. Prostate1992; 20: 311. Google Scholar 15 : Studies on immunocytochemical localization of inhibin-like material in human prostate tissue: comparison of its distribution in normal, benign and malignant prostates. Br J Cancer1986; 53: 547. Google Scholar 16 : Further studies on the synthesis and secretion of inhibin-like material by rat ventral prostate explants in vitro. Prostate1990; 16: 163. Google Scholar 17 : Detection of prostatic-inhibin-like peptide in the cytoplasm of LNCaP cells, a human prostatic adenocarcinoma cell line. Prostate1994; 24: 285. Google Scholar 18 : Recombinant PSP94 (prostate secretory protein of 94 amino acids) demonstrates similar linear epitope structure as natural PSP94 protein. J Cell Biochem1996; 63: 61. Google Scholar 19 : Analysis of epitope structure of PSP94 (prostate secretory protein of 94 amino acids): (I) immuno-dominant and immuno-recessive area. J Cell Biochem1997; 65: 172. Google Scholar 20 : Analysis of epitope structure of PSP94 (prostate secretory protein of 94 amino acids): (II) Epitope mapping by monoclonal antibodies. J Cell Biochem1997; 65: 185. Google Scholar 21 : Histological grading of prostate cancer: a perspective. Hum Pathol1992; 23: 273. Google Scholar 22 : Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology1997; 49: 16. Google Scholar 23 : cDNA, genomic cloning and gene expression analysis of mouse PSP94 (prostate secretory protein of 94 amino acids). DNA Cell Biol1999; 18: 11. Google Scholar 24 : PSP94 (or β-microseminoprotein) is a secretory protein specifically expressed and synthesized in the lateral lobe of the rat prostate. Prostate2000; 42: 219. Google Scholar 25 : Lobe-specific apoptotic cell death in rat prostate after androgen ablation by castration. Endocrinology1995; 136: 4368. Google Scholar 26 : Excretion of three major prostatic secretory proteins in the urine of normal men and patients with benign prostatic hypotrophy or prostate cancer. Prostate1987; 10: 235. Google Scholar From the Departments of Surgery and Pathology, University of Western Ontario, London, Ontario, Canada, and Department of Urology, Nagasaki University School of Medicine, Nagasaki, Japan© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 164Issue 5November 2000Page: 1819-1824 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.Keywordsandrogensprostatic neoplasmshormonesimmunohistochemistryMetricsAuthor Information YUSHI IMASATO More articles by this author JIM W. XUAN More articles by this author HIDEKI SAKAI More articles by this author JONATHAN I. IZAWA Financial interest and/or other relationship with M.D. Anderson Cancer Center. More articles by this author YUTAKA SAITO More articles by this author JOSEPH L. CHIN More articles by this author MADELEINE MOUSSA More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
- W2098588789 created "2016-06-24" @default.
- W2098588789 creator A5042305864 @default.
- W2098588789 creator A5046786824 @default.
- W2098588789 creator A5046888497 @default.
- W2098588789 creator A5055091318 @default.
- W2098588789 creator A5062501400 @default.
- W2098588789 creator A5068360532 @default.
- W2098588789 creator A5079627883 @default.
- W2098588789 date "2000-11-01" @default.
- W2098588789 modified "2023-10-18" @default.
- W2098588789 title "PSP94 EXPRESSION AFTER ANDROGEN DEPRIVATION THERAPY: A COMPARATIVE STUDY WITH PROSTATE SPECIFIC ANTIGEN IN BENIGN PROSTATE AND PROSTATE CANCER" @default.
- W2098588789 cites W1966471381 @default.
- W2098588789 cites W1976137755 @default.
- W2098588789 cites W1980633528 @default.
- W2098588789 cites W1982865501 @default.
- W2098588789 cites W1994834679 @default.
- W2098588789 cites W2011120797 @default.
- W2098588789 cites W2013713901 @default.
- W2098588789 cites W2016973566 @default.
- W2098588789 cites W2018564413 @default.
- W2098588789 cites W2023480185 @default.
- W2098588789 cites W2047387328 @default.
- W2098588789 cites W2051323179 @default.
- W2098588789 cites W2053007597 @default.
- W2098588789 cites W2053243641 @default.
- W2098588789 cites W2060860221 @default.
- W2098588789 cites W2061317403 @default.
- W2098588789 cites W2062700146 @default.
- W2098588789 cites W2063655363 @default.
- W2098588789 cites W2083583090 @default.
- W2098588789 cites W2084455963 @default.
- W2098588789 cites W2114774008 @default.
- W2098588789 cites W2128590829 @default.
- W2098588789 cites W2129122136 @default.
- W2098588789 cites W2290701675 @default.
- W2098588789 cites W4238525400 @default.
- W2098588789 doi "https://doi.org/10.1016/s0022-5347(05)67113-3" @default.
- W2098588789 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11025776" @default.
- W2098588789 hasPublicationYear "2000" @default.
- W2098588789 type Work @default.
- W2098588789 sameAs 2098588789 @default.
- W2098588789 citedByCount "36" @default.
- W2098588789 countsByYear W20985887892012 @default.
- W2098588789 countsByYear W20985887892013 @default.
- W2098588789 countsByYear W20985887892014 @default.
- W2098588789 countsByYear W20985887892016 @default.
- W2098588789 countsByYear W20985887892017 @default.
- W2098588789 countsByYear W20985887892018 @default.
- W2098588789 countsByYear W20985887892019 @default.
- W2098588789 countsByYear W20985887892020 @default.
- W2098588789 countsByYear W20985887892021 @default.
- W2098588789 countsByYear W20985887892022 @default.
- W2098588789 countsByYear W20985887892023 @default.
- W2098588789 crossrefType "journal-article" @default.
- W2098588789 hasAuthorship W2098588789A5042305864 @default.
- W2098588789 hasAuthorship W2098588789A5046786824 @default.
- W2098588789 hasAuthorship W2098588789A5046888497 @default.
- W2098588789 hasAuthorship W2098588789A5055091318 @default.
- W2098588789 hasAuthorship W2098588789A5062501400 @default.
- W2098588789 hasAuthorship W2098588789A5068360532 @default.
- W2098588789 hasAuthorship W2098588789A5079627883 @default.
- W2098588789 hasConcept C121608353 @default.
- W2098588789 hasConcept C126322002 @default.
- W2098588789 hasConcept C143998085 @default.
- W2098588789 hasConcept C2776235491 @default.
- W2098588789 hasConcept C2777899217 @default.
- W2098588789 hasConcept C2777911890 @default.
- W2098588789 hasConcept C2780192828 @default.
- W2098588789 hasConcept C2781406297 @default.
- W2098588789 hasConcept C71315377 @default.
- W2098588789 hasConcept C71924100 @default.
- W2098588789 hasConcept C87874733 @default.
- W2098588789 hasConceptScore W2098588789C121608353 @default.
- W2098588789 hasConceptScore W2098588789C126322002 @default.
- W2098588789 hasConceptScore W2098588789C143998085 @default.
- W2098588789 hasConceptScore W2098588789C2776235491 @default.
- W2098588789 hasConceptScore W2098588789C2777899217 @default.
- W2098588789 hasConceptScore W2098588789C2777911890 @default.
- W2098588789 hasConceptScore W2098588789C2780192828 @default.
- W2098588789 hasConceptScore W2098588789C2781406297 @default.
- W2098588789 hasConceptScore W2098588789C71315377 @default.
- W2098588789 hasConceptScore W2098588789C71924100 @default.
- W2098588789 hasConceptScore W2098588789C87874733 @default.
- W2098588789 hasIssue "5" @default.
- W2098588789 hasLocation W20985887891 @default.
- W2098588789 hasLocation W20985887892 @default.
- W2098588789 hasOpenAccess W2098588789 @default.
- W2098588789 hasPrimaryLocation W20985887891 @default.
- W2098588789 hasRelatedWork W1497253641 @default.
- W2098588789 hasRelatedWork W2017040238 @default.
- W2098588789 hasRelatedWork W2021846196 @default.
- W2098588789 hasRelatedWork W2063619085 @default.
- W2098588789 hasRelatedWork W2082569851 @default.
- W2098588789 hasRelatedWork W2131098924 @default.
- W2098588789 hasRelatedWork W2140855177 @default.
- W2098588789 hasRelatedWork W2170823000 @default.
- W2098588789 hasRelatedWork W2354678759 @default.